Compare Newegg Commerce Inc (NEGG) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Newegg Commerce Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Newegg Commerce Inc trades at $14.93 (market cap $315.03M), while Vertex Pharmaceuticals Incorporated trades at $519.32 (market cap $134.06B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 425.5× Newegg Commerce Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Newegg Commerce Inc nearer its low. Which is the better fit depends on your goals.
| NEGG | VRTX | |
|---|---|---|
Market Cap | $315.03M | $134.06B |
Sector | Consumer Cyclical | Health |
52-Week High | $92.74 | $557.96 |
52-Week Low | $12.87 | $376.62 |
Enterprise Value | $285.26M | $128.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NEGG trades at $15.17, down 0.98% on the day, with a bearish technical signal but improving fundamentals. Recent quarterly earnings consistently beat expectations, including Q2 2026 EPS of $0.11 versus -$0.40 estimated. Revenue stabilized around $1.4 billion in 2025-2026, with net income turning positive in 2026. The company announced partnerships with Hewlett Packard Enterprise and launched AI shopping features, indicating strategic growth initiatives.
The outlook is cautiously optimistic due to earnings momentum and low P/S ratio of 0.23, but risks include negative operating cash flow in 2025 and high current liabilities. Analyst consensus is 100% buy, though based on limited coverage. Investors should weigh profitability improvements against liquidity concerns and competitive e-commerce pressures.
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, with a bullish technical signal and strong fundamentals. The stock shows robust profitability with an 86% gross margin and 35% net margin, supported by $12.0B revenue in 2025. Recent acquisition of Crinetics Pharmaceuticals expands its pipeline, while analyst consensus remains strongly bullish with an 85.7% buy rating and a $548.78 price target.
Outlook is positive driven by revenue growth and pipeline expansion, but risks include clinical setbacks and competition. The stock offers upside to the consensus target, with cash flow recovery in 2025 signaling operational strength. Investors should weigh high valuation multiples against earnings consistency and market sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Newegg Commerce Inc
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home and gaming products and provides certain third-party logistics services globally.
Read more on NEGG →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
